We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sargramostim

News List

Leukine Trial in Hospitalized COVID-19 Patients Meets Primary Endpoint americanpharmaceuticalreview
March 03, 2021
Partner Therapeutics (PTx) announced top-line results of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine® (sargramostim, yeast-derived recombinant human GM-CSF) ...
Partner Therapeutics’ inhaled sargramostim improves lung function in trial pharmaceutical-technology
March 02, 2021
Partner Therapeutics has reported positive top-line results from the investigator-led study of inhaled Leukine (sargramostim) in hospitalised Covid-19 patients.
Leukine® significantly improves lung function in hospitalised COVID-19 patients europeanpharmaceuticalreview
March 01, 2021
In the trial Leukine® (sargramostim, rhuGM-CSF) improved oxygenation in COVID-19 patients with acute respiratory failure by at least a third in over half of those treated.